CEO Update | 27 June 2022

Key investment shows competitiveness of the UK ecosystem

I was delighted to see the announcement from Moderna that it has chosen the UK to base its mRNA Innovation and Technology Centre and an additional mRNA manufacturing centre. Alongside other recent investments from the likes of Fujifilm and ThermoFisher, the UK is now superbly placed to ensure the next generation of therapeutics and vaccines are developed and manufactured for the globe right here within our world-class ecosystem. It is another proof point of what I’ve been saying at international conferences this year - the UK has unique assets and capabilities that make it the most efficient place to spend your biotech bucks. 

On which note, invoX Pharma, a subsidiary of Hong Kong’s Sino Biopharm, has pledged major investment in Cambridge operations following its $161 million cash acquisition of long-standing BIA member F-star Therapeutics. It is great to see global companies like Sino Biopharm seeing the value of putting UK biotech at the heart of their R&D platform. Without a doubt, we will be seeing more M&A deals of promising UK companies in the coming months.

Looking to Westminster

As last week’s by-election results reverberate around the corridors of Whitehall and Westminster, we are focused on the key issues that matter most to our members. Today I am meeting with the Pensions Minister, Guy Opperman MP, and the Chancellor’s Parliamentary Private Secretary, Craig Williams MP, to talk about what more can be done to increase investment from the City of London into innovative UK businesses.

On Thursday, CEOs from our member companies will be joining the BIA team for our 22nd annual Parliament Day. This is our flagship influencing day when our members get the opportunity to speak directly to ministers, MPs and civil servants to tell them what the Government can do to support our industry. We will be delivering key messages on increasing public and private investment into start-ups and scale-ups, improving patients’ access to innovative medicines, and supporting emerging technologies, like genomics and engineering biology. Places are full but keep a lookout on our social media channels for photos of the day’s proceedings.

MHRA announcement on medical devices

In regulatory developments the Medicines and Healthcare products Regulatory Agency (MHRA) has published the government’s response to the Future Regulation of Medical Devices in the United Kingdom Consultation. The agency is committed to engagement with industry and stakeholders whilst refining legislation and implementing changes. The MHRA will gradually phase in the new requirements with transitional arrangements to give the industry enough time to adapt to the change.

Thank you to everyone who attended our two fantastic conferences last week

It was great to see so many senior CEOs from our sector sharing their experiences with the next generation of talent at our Life Sciences Leadership Summit in sunny Hertfordshire on Monday and Tuesday. As always, the programme was a mix of informative workshops, provocative panels and late-night networking.

As the Medicines Manufacturing Industry Partnership (MMIP) annual conference moved online due to the rail strikes on Tuesday fleet of foot organisation ensured we continued to have a range of interesting panels and presentations, and a positive keynote speech from Science Minister George Freeman MP. We look forward to this community coming together at the bioProcess UK conference later in the year.

Steve circle.png

 

 

Steve Bates OBE
CEO, BioIndustry Association


More news and updates

BIA Update | 15 August 2022

With the August lull and many people taking well-earned breaks, at BIA we are forging ahead with planning new events and new directions for 2023. As BIA membership continues to grow and thrive we face the challenge of continuing to connect and engage effectively with ever larger numbers of member companies and their employees, and we’re looking to address this with additional capabilities and exciting new initiatives.

EngBio Innovator Spotlight: bit.bio/Meatable

UK companies are working across a diverse range of applications of engineering biology. Featured in the 'Power of Biology: The UK is engineering biology for global good' report, the following case study highlights bit.bio/Meatable and gives additional insight into how this transformative technology can be used across healthcare, industry and agriculture. 

CEO Update | 8 August 2022

Summertime can be a quiet time but there has been a string of high-profile announcements within the UK sector to celebrate. Last week, RoslinCT announced that they have signed a business combination agreement with US advanced therapy CDMO Lykan Biosciences to form a global leading innovative advanced therapies CDMO. Read more on our engagement with the Labour Party and Biomedical Catalyst Round 2.

TechBio innovator spotlight: Faster, more accurate diagnosis of prostate cancer

Suspected prostate cancer cases need a biopsy, 80% of which result in complications. Improving diagnosis, using artificial intelligence with patient MRI scans, will reduce the risk of complications and speed up diagnosis.

More within